On the stock market since 2020, it operates in the world of health and science. It has 342 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 367% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Sales are growing strongly for its sector.
Clearly above the class average — a step short of the very top.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Executive Buying: The trades send no strong signal of confidence.
The stock trades 20% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 367% a year on average.
Sales run at $376.1M a year. A small number, but proof the product has real buyers.
There is $221.0M in the vault; even if every debt were paid off, $214.7M would remain.
A loss of $16.1M against $376.1M in annual sales.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 42/100.
No clear buy-side message is coming from the executive floor. Council score: 3/10.
On our five-subject report card, ARQT sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: ARQT is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (60/100) says the stock isn’t cheap.